linjc16/ctgov huggingface dataset:
Bronchi Dilation in Polynesian Patients: Monocentric Retrospective Study

Study Overview
=================
Brief Summary
-----------------
The study hypothesis is that dilations of idiopathic bronchi are particularly common in French Polynesia, and that there are arguments in favour of an underlying genetic factor. The study will retrieve retrospective data in the history of bronchial dilation, patients' personal and family history, microbiological and scannographic data, and the latest cardio respiratory checkup.

Official Title
-----------------
Bronchi Dilation in Polynesian Patients: Monocentric Retrospective Study

Conditions
-----------------
Polynesian Bronchiectasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Polynesian patient Patient with bronchial dilation followed by Centre hospitalier de Polynesie Francaise or patient with bonchial dilation no longer consulting in the hospital over the study period Jan 1, 2010 to Dec 31, 2020 Exclusion Criteria: Expressed refusal to participate in the study for patients undergoing follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe the detailed phenotype of bronchi dilation in the Polynesian population | Clinical criteria: age of onset, personal or family history, smoking Changes in respiratory function Infectious complications: types of bronchial colonization (bacterial, mycobacterial and mycological) Scantographic aspect: Appearance of bronchectasis: cylindrical, varicose orcious, cystic Distributions: LSD, LM, LID, LSG, LIG | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Highlighting indirect arguments for a genetic cause | Age of onset of symptoms, frequency of so-called idiopathic bronchi dilatation, frequency of inbreeding, familial history | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bronchi dilatation
Primary Patency in Post-angioplasty Dysfunctional Arteriovenous Fistula in Renal Dialysis: Paclitaxel-releasing PTA Balloon Catheter vs PTA Balloon

Study Overview
=================
Brief Summary
-----------------
In recent years the use of paclitaxel releasing percutaneous transluminal angioplastic (PTA) balloon catheter is spreading in vascular pathology, mainly in stenosis infrainguinal arteries. This device combined the mechanical action of PTA balloon with the antiproliferative effects of paclitaxel. The use of these devices in venous pathology is limited. This devices could improve the treatment of renal dialysis arteriovenous fistula stenosis.

Conditions
-----------------
Arteriovenous Fistula Renal Dialysis Devices Obstruction

Intervention / Treatment
-----------------
* Device: Paclitaxel-releasing PTA balloon catheter
* Device: PTA balloon catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with renal dialysis with arteriovenous fistula (AVF) at least 3 months before. Patient diagnosed with AVF stenosis by clinical and radiological criteria Sign informed consent Exclusion Criteria: Pregnant or breastfeeding Patients with AVF stenosis not could be treated with PTA catheter Paclitaxel allergy Iodinated contrast allergy Local or systemic active infection Life expectancy less than 12 moths

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Paclitaxel-releasing PTA balloon catheter<br>Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter. | Device: Paclitaxel-releasing PTA balloon catheter<br> <br> |
| Active Comparator: PTA Balloon catheter<br>Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter. | Device: PTA balloon catheter<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Freedom from target lesion revascularization | Percentage of patients that do not need any revascularization proceeding during the following twelve months after catheter insertion. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vascular access devices obstruction
Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Study Overview
=================
Brief Summary
-----------------
This is a multicentre, multinational clinical study. It comprised two consecutive segments (A and B). Segment A was designed as a randomized, double-blind, double-dummy, active-controlled, two-arm parallel-group study. The patients received either budesonide or prednisone for 6 months. During segment B all patients received budesonide as an open treatment for additional 6 months. In this confirmatory study the proportion of patients with complete response was compared between the two treatment groups. Complete response was defined as biochemical remission (=serum levels of ASAT and ALAT within normal ranges) at the individual last visit of segment A and lack of steroid specific side effects throughout segment A.

Official Title
-----------------
Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-blind, Randomized, Active-controlled, Multicentre Study

Conditions
-----------------
Autoimmune Hepatitis

Intervention / Treatment
-----------------
* Drug: budesonide
* Drug: prednisone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 10 to 70 years Diagnosis of acute AIH according to Alvarez score normal range of TPMT activity normal ACTH test negative pregnancy test at screening for females of childbearing potential written informed consent Exclusion Criteria: presence of Hepatitis A, B, C, E or G virus infection liver cirrhosis or clinical signs of portal hypertension PBC PSC history of hypersensitivity to the study medication

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: budesonide<br>3mg capsules 3x/day for 6 months | Drug: budesonide<br>* 3mg capsule, 3x per day for 6 months<br>|
| Active Comparator: prednisone<br>5mg tablet, 40mg starting dose titrated to 10mg over 3 months | Drug: prednisone<br>* 5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical remission (=serum levels of ASAT and ALAT within normal ranges) at the individual last visit of Segment A and lack of steroid specific side effects |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of biochemical remission |  | 6 months |
Wearable Devices to Monitor Seizures in Autoimmune Epilepsy

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to search for reproducible changes in a wide range of physical signals, including heart rate, muscle tone and activity and EEG before and at the onset of seizures in patients with epilepsy.

Official Title
-----------------
Managing Multiple Seizure Types With Wearable Devices

Conditions
-----------------
Healthy, Autoimmune Epilepsy

Intervention / Treatment
-----------------
* Device: Biosensor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with or suspected of having autoimmune epilepsy. Normal controls - cognitively normal subjects without epilepsy Exclusion Criteria: • Cognitive or psychiatric condition rendering patient unable to cooperate with data collection or manage and recharge smart watch and tablet computer devices. Presence of open or healing wounds near monitoring sites (infection risk).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Autoimmune Epilepsy with Biosensors<br>Subjects with suspected autoimmune epilepsy will wear biosensors on wrist or upper arm during the at home monitoring period. | Device: Biosensor<br>* Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days<br>|
| Active Comparator: Healthy Controls with Biosensors<br>Neurologically normal adult healthy controls will wear biosensors on wrist or upper arm during the at home monitoring period. | Device: Biosensor<br>* Noninvasive wearable biosensor device worn on the primary affected wrist or upper arm for as much time as is feasible for 7-10 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of high-quality physiological signals | Total number of high-quality physiological signals recorded by biosensors | 10 days | 
| Number of Reproducible changes in physiological biosignals | Identification of reproducible changes in one or more physiological biosignals at onset of video and/or EEG-identified seizures | 10 days |
Endoscopic Ultrasound Staging of Periampullary Neoplasms: Retrospective

Study Overview
=================
Brief Summary
-----------------
The purpose of this retrospective study is to determine the degree to which a biliary stent affects EUS staging accuracy of ampullary tumors.

Official Title
-----------------
EUS Staging Accuracy of Periampullary Neoplasms: a Retrospective Review

Conditions
-----------------
Periampullary Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will be identified retrospectively through an existing Indiana University Medical Center EUS database and pathology database. Patients with and without biliary stents will be included. Exclusion Criteria: Patients that were suspected to have ampullary tumors but who were ultimately found to have a normal ampulla will be excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The presence of a biliary stent decreases EUS staging accuracy due to the intervening shadow artifacts |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EUS, periampullary neoplasms
Safety of Undenatured Collagen Type II (UCII) Supplement in Healthy Volunteer

Study Overview
=================
Brief Summary
-----------------
This study will be evaluated safety of undenatured collagen type II (UCII) supplement in 60 healthy volunteer. Liver function test, renal function test, and adverse event will be assessed.

Detailed Description
-----------------
This study will be evaluated safety of undenatured collagen type II (UCII) supplement in 60 healthy volunteer. The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months. Liver function test, renal function test, and adverse event will be assessed before and after taking for 1 and 2 months.

Official Title
-----------------
Safety of Undenatured Collagen Type II (UCII) Supplement in Healthy Volunteer

Conditions
-----------------
Health, Subjective

Intervention / Treatment
-----------------
* Dietary Supplement: undenatured collagen type II (UCII) supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20-60 years No taking collagen supplement more than 2 weeks No collagen and protein allergy No liver and renal disease Have a willingness to participate in the study Exclusion Criteria: Uncontrolled disease Have complication symptom during study Pregnancy or lactation Cannot follow the protocol During participated in other studies

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: undenatured collagen type II (UCII) supplement<br>The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months. | Dietary Supplement: undenatured collagen type II (UCII) supplement<br>* The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.<br>* Other names: UCII;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aspartate aminotransferase value | Aspartate aminotransferase value (U/L) in blood sample | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alkaline phosphatase value | Alkaline phosphatase value (U/L) in blood sample | 2 months | 
| Alanine transaminase value | Alanine transaminase value(U/L) in blood sample | 2 months | 
| Blood urea nitrogen value | Blood urea nitrogen value (mg/dl) in blood sample | 2 months | 
| Creatinine value | Creatinine value (mg/dl) in blood sample | 2 months | 
| Adverse event | using questionnaire (Yes or No) | 2 months |
Effects of Magnesium Oil Application on the Muscle Contractile Properties

Study Overview
=================
Brief Summary
-----------------
This study will aim to investigate the effects of magnesium oil administration on skeletal muscle contractile properties.

Detailed Description
-----------------
Aim: This study will aim to investigate the effects of magnesium oil administration on skeletal muscle contractile properties (SMcp). Design: Randomized controlled study Participants: For this purpose, investigators will recruit 40 recreationally active and healthy adults of both sexes (18-35 years of age). Methods: The experimental leg (EXP) will receive the 10 sprays of magnesium oil (20 mg per spray) that will be topically applied to the skin covering the knee extensor muscles, whereas the control leg (CON) will receive 10 sprays of natural mineral-free oil. The vastus lateralis SMcp will be measured by using a tensiomyography (TMG) device before application (PRE) and after 10 (POST10), 20 (POST20), 30 (POST30), 40 (POST40), and 50 (POST50) minutes of application onset, respectively.

Official Title
-----------------
Effects of Magnesium Oil Application on the Muscle Contractile Properties

Conditions
-----------------
Magnesium, Skeletal Muscle Contraction Properties

Intervention / Treatment
-----------------
* Other: Magnesium oil (BetterYou) dermal application
* Other: Placebo Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy, recreationally active adults, no history of neuromuscular and musculoskeletal diseases Exclusion Criteria: if some of the criteria are not met

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized controlled study
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental<br>Magnesium oil application | Other: Magnesium oil (BetterYou) dermal application<br>* 10 sprays (200 mg) of magnesium oil (BetterYou) will be applied to skin covering knee extensor muscles. The magnesium oil will be applied only once<br>|
| Placebo Comparator: Control<br>Natural mineral-free oil application | Other: Placebo Control<br>* Natural mineral-free oil (10 sprays) will be applied as the control condition. This will be done only once<br>* Other names: CONTROL;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skeletal Muscle Contractile Properties | Skeletal muscle contractile properties will be measured by using tensiomyography device | 75 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tensiomyography, Skeletal Muscle, Contractile Properties
Effectiveness of TheraNeem Lip Therapy for Herpes Simplex Labialis

Study Overview
=================
Brief Summary
-----------------
This study intends to test the efficacy of the TheraNeem Lip Therapy balm for Herpes Simplex. The study will include a total of 5 people.

Detailed Description
-----------------
Qualified candidates will be officially enrolled into the study within 24 hours of their subsequent outbreak of Herpes Simplex Labialis. They will be given all of the Neem Therapy products to use, and photographs and questionnaires will be taken to assess their progress.

Official Title
-----------------
Effectiveness of TheraNeem Lip Therapy of Common Symptoms of Herpes Simplex Labialis A Prospective Experimental Case Series (n=5)

Conditions
-----------------
Herpes Simplex

Intervention / Treatment
-----------------
* Other: Neem Based External Application Cream


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant has signs and symptoms of HSV-1 infection of less than 24 hours duration to the Southern California University of Health Sciences investigators Participants ages 18-70 years Confirmation of oral-circumoral herpes lesion will be made by a clinician in the presence of oral-circumoral lesion assumed to be HSV-1 for purposes of study Subjects expressed willingness to comply with protocol Subject will be willing to have the presenting lesion photographed twice Subject sign a written informed consent, HIPPA disclosure, Experimental bill of rights Exclusion Criteria: History of past or present immunosuppressive condition, or currently taking immunosuppressive medication History of adverse effects or allergies to any Neem based product or containing any of the other ingredients TheraNeem Lip Therapy: Organic Coconut Oil, Organic Beeswax, Organic Jojoba Oil, Shea Butter, Sesame Oil, Organic Neem Oil, , Essential Oil of Peppermint, Vitamin E (Tocopherol) Signs of disseminated HSV illness History of use of oral or topical antiviral agents within 10 days of screening and/or at start of study visit Pregnancy or lactation Psychiatric disorder Inability to understand or follow the instructions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: External Application of Neem-based Cream<br>Non Controlled, non-randomized, single group pilot study. | Other: Neem Based External Application Cream<br>* Apply externally 3-4 times per day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cold Sore Symptom Scale |  | Baseline and End of Treatment |